greeksoup/ stock research

Immunome Inc. insider trading

In twelve months insiders at Immunome bought $2.3M and sold $27.5M on the open market; 24 of the 28 sales were under plans set months before.

Bought on the open market$2.3M11 purchases
Sold on the open market$27.5M28 sales
Sales set in advance24 of 28under Rule 10b5-1 plans
Pay taken in stockNone
New to this? How to read this page
  1. Insiders are the people who run the company: officers, directors and owners of 10% or more. They must report a trade on Form 4 within two business days.
  2. A purchase on the open market is the strongest sign: the insider spent their own money.
  3. A sale under a trading plan (Rule 10b5-1) says little: its dates were fixed months before. Sales outside a plan say more, but insiders sell for many reasons, such as taxes or a house.
  4. Grants, option exercises and shares held back for tax are left out.
  5. What is a Form 4? · Form 4 codes

What kind of trades

11 purchases worth $2.3M against 28 sales worth $27.5M; 24 of the sales were under plans set months before.

Purchasebought with their own money
Pay in stock, own choiceowed cash, chose shares
Sale outside a planthe insider picked the day
Sale under a plandates fixed months before
Says littlecompany plans, board pay, cash units
Bought
11 open market
Sold
424 under a plan

Every Form 4 line of the last twelve months, counted by kind. The grades come from the filing itself: whether the insider paid cash, whether a plan set the date, whether pay was taken in stock by choice.

Insider trades on the share price

last twelve months

30 marks over twelve months, each in its grade: solid for the stronger signs, hollow or grey for the ones that say little.

PurchasePay in stock, own choiceSale outside a planSale under a planSays little

The blue line is the daily close over twelve months. Each mark is one insider's trades on one day, on that day's price, sized by dollar value. Solid marks are the stronger signs; hollow and grey marks say little. Hover or tap a mark for who, how much and why.

Trades worth a closer look

A purchase stands out when two or more of these hold: a senior insider, several insiders buying within 90 days, a fall of 10% or more in the three months before, or over $1 million. A sale outside a plan is judged the same way. These are the Feed's rules.

Who traded

dollars, twelve months

9 insiders traded. The most: Barchas Isaac, sale under a plan $18.3M.

One row per insider, sold to the left and bought to the right, split by grade: the paler part of a bar is the part that says little.

How it compares

every company on the site

Open-market sales, twelve months

Open-market purchases, twelve months

    The bar ranks every company on the site from the lowest on the left to the highest on the right, in three equal thirds; the small figures under it are the values where each third starts, and the black tick is the middle company. The orange dot is this company; the grey ticks are the other companies in its industry (hover or tap for names). A hatched block is companies tied at none.

    Every Form 4 line

    Purchase: bought on the open market with their own moneyTook pay in stock, own choice: owed cash, chose shares instead; a softer signSale: sold on the open market, not under a plan set in advanceSale, trading plan: under a Rule 10b5-1 plan set up months before, so the date was fixed in advanceGrey lines: plan purchases, pay in stock taken by the whole board or under a company plan, and units paid in cash; they say little about the insider's own view
    TradedInsiderRoleTypeSharesPriceValueFiling
    11 September 2026Higgins JackChief Scientific OfficerSaletrading plan set in advance · Form 144 notice 11 September 202613,200$25.32$334,224Form 4
    12 August 2026Barchas IsaacDirectorSaletrading plan set in advance · Form 144 notice 12 August 202611,048$27.25$301,058Form 4
    11 August 2026Barchas Isaac, see footnoteDirectorSaletrading plan set in advance · Form 144 notice 12 August 202662,291$26.23$1.6 millionForm 4
    10 August 2026Barchas Isaac, see footnoteDirectorSaletrading plan set in advance10,125$26.07$263,959Form 4
    7 August 2026Barchas Isaac, see footnoteDirectorSaletrading plan set in advance15,248$26.06$397,363Form 4
    6 August 2026Barchas Isaac, see footnoteDirectorSaletrading plan set in advance20,840$26.06$543,090Form 4
    4 August 2026Horn KinneyChief Business OfficerSaletrading plan set in advance · Form 144 notice 4 August 202690,616$25.09$2.3 millionForm 4
    7 July 2026Horn KinneyChief Business OfficerSaletrading plan set in advance · Form 144 notice 7 July 20261,092$25.00$27,300Form 4
    7 July 2026Barchas Isaac, see footnoteDirectorSaletrading plan set in advance16,906$24.20$409,125Form 4
    6 July 2026Barchas Isaac, see footnoteDirectorSaletrading plan set in advance83,094$24.11$2.0 millionForm 4
    2 July 2026Lechleider RobertChief Medical OfficerSaletrading plan set in advance · Form 144 notice 2 July 202622,714$21.95$498,572Form 4
    2 July 2026Lechleider RobertChief Medical OfficerSaletrading plan set in advance · Form 144 notice 2 July 202616,214$22.76$369,031Form 4
    2 July 2026Lechleider RobertChief Medical OfficerSaletrading plan set in advance · Form 144 notice 2 July 202616,072$23.44$376,728Form 4
    2 July 2026Barchas Isaac, see footnoteDirectorSaletrading plan set in advance75,665$22.35$1.7 millionForm 4
    2 July 2026Barchas Isaac, see footnoteDirectorSaletrading plan set in advance24,335$23.33$567,736Form 4
    30 June 2026Barchas Isaac, see footnotesDirectorSaletrading plan set in advance101,050$21.12$2.1 millionForm 4
    25 June 2026Lechleider RobertChief Medical OfficerSaletrading plan set in advance · Form 144 notice 25 June 202640,580$19.56$793,745Form 4
    25 June 2026Lechleider RobertChief Medical OfficerSaletrading plan set in advance · Form 144 notice 25 June 202614,420$20.66$297,917Form 4
    15 June 2026Rosett MaxChief Financial OfficerSaletrading plan set in advance · Form 144 notice 15 June 202660,000$18.23$1.1 millionForm 4
    5 June 2026Bienaime Jean JacquesDirectorSaleafter a 12% fall over three months · 31% below its one-year high500$19.44$9,720Form 4
    5 June 2026Bienaime Jean JacquesDirectorSaleafter a 12% fall over three months · 31% below its one-year high10,000$19.41$194,100Form 4
    5 June 2026Bienaime Jean JacquesDirectorPurchaseafter a 12% fall over three months · 31% below its one-year high6,000$19.48$116,880Form 4
    5 June 2026Bienaime Jean JacquesDirectorPurchaseafter a 12% fall over three months · 31% below its one-year high3,500$19.46$68,110Form 4
    5 June 2026Bienaime Jean JacquesDirectorPurchaseafter a 12% fall over three months · 31% below its one-year high1,000$19.27$19,270Form 4
    15 May 2026Bienaime Jean JacquesDirectorPurchaseafter a 6% fall over three months · 23% below its one-year high5,000$20.70$103,500Form 4
    2 April 2026Higgins JackChief Scientific OfficerSaletrading plan set in advance · Form 144 notice 2 April 20269,438$21.64$204,238Form 4
    2 April 2026Rosett MaxChief Financial OfficerSaletrading plan set in advance · Form 144 notice 2 April 202663,656$21.91$1.4 millionForm 4
    2 April 2026Rosett MaxChief Financial OfficerSaletrading plan set in advance · Form 144 notice 2 April 20261,344$22.48$30,213Form 4
    27 March 2026Siegall Clay BPresident and CEOPurchaseafter a 10% fall over three months · 27% below its one-year high25,450$19.67$500,602Form 4
    23 March 2026Wagenheim PhilipDirectorSaleafter a 6% fall over three months · 23% below its one-year high · Form 144 notice 20 March 202628,200$20.65$582,330Form 4
    20 March 2026Wagenheim PhilipDirectorSaleafter a 7% fall over three months · 26% below its one-year high · Form 144 notice 20 March 202636,800$20.47$753,296Form 4
    11 March 2026Bienaime Jean JacquesDirectorPurchaseafter a 5% rise over three months · 21% below its one-year high1,000$21.55$21,550Form 4
    10 March 2026Bienaime Jean JacquesDirectorPurchaseafter a 15% rise over three months · 19% below its one-year high1,000$22.12$22,120Form 4
    30 December 2025Siegall Clay BPresident and CEOPurchaseafter a 81% rise over three months · 10% below its one-year high4,729$21.15$100,018Form 4
    22 December 2025Barchas Isaac, see footnotesDirectorSaletrading plan set in advance371,949$21.72$8.1 millionForm 4
    22 December 2025Barchas Isaac, see footnoteDirectorSaletrading plan set in advance11,251$22.34$251,347Form 4
    19 December 2025Siegall Clay BPresident and CEOPurchaseafter a 128% rise over three months · 9% below its one-year high7,278$20.48$149,053Form 4
    19 December 2025Tsai PhilipChief Technical OfficerPurchaseafter a 128% rise over three months · 9% below its one-year high10,000$20.49$204,900Form 4
    18 December 2025Siegall Clay BPresident and CEOPurchaseafter a 103% rise over three months · 15% below its one-year high46,511$21.50$999,986Form 4
    A filing with several lines appears once per line.
    Read morePay taken in stock by the insider's own choice has the filing's footnote, word for word, in the note under it; for the others, hold the pointer on the type. An award filed at no price shows n/a.